Maryam S Daneshpour - PhD, Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, I.R.

Personalized Medicine has the potential to improve health outcomes and reduce the cost of care; however, its adoption has been slow in developing countries like Iran. Pharmacogenetics (PGx) is an application of personalized medicine, referring to the process where patients are stratified and treated based on their genetic profile, which is used to assess expected drug response and the risk of adverse side effects. Non-communicable disorders like cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes are the main problem in this issues. Metabolic syndrome is a cluster of conditions consist of increased blood pressure, high blood sugar, excess body fat around the waist, and abnormal cholesterol or triglyceride levels that occur together, increasing the risk of heart disease, stroke, and diabetes. This condition could be defined every individual because 3 of 5 conditions is enough for this syndrome. Each of these conditions has own the genetic risk factors and the complex of them have different genetic relationship. Iran with the population more than 80 million and variety of ethnicity faced to serious drawback for detecting individualized medicine. Tehran cardio-metabolic genetic study (TCGS) with possession of chip data and whole genome sequencing information for more than 15000 individuals have a good genetic infrastructure for analyzing the genetic aspect of metabolic syndrome and using in a purpose of individualized medicine.